Turning Point Therapeutics, Inc. Proceeds from Stock Plans
Turning Point Therapeutics, Inc. reported Proceeds from Stock Plans of $9.37 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2022-08-08
- Turning Point Therapeutics, Inc. proceeds from stock plans for the quarter ending 2022-06-30 was $8.97M, a 3.93% decline year-over-year.
- Turning Point Therapeutics, Inc. proceeds from stock plans for the quarter ending 2022-03-31 was $396.00K, a 95.91% decline year-over-year.
- Turning Point Therapeutics, Inc. proceeds from stock plans for the quarter ending 2021-12-31 was $2.60M, a 78.65% decline year-over-year.
- Turning Point Therapeutics, Inc. proceeds from stock plans for the quarter ending 2021-09-30 was $2.38M, a 368.31% increase year-over-year.
- Turning Point Therapeutics, Inc. proceeds from stock plans for fiscal 2021 was $24.00M, a 80.90% increase from fiscal 2020.
- Turning Point Therapeutics, Inc. proceeds from stock plans for fiscal 2020 was $13.27M, a 890.96% increase from fiscal 2019.
- Turning Point Therapeutics, Inc. proceeds from stock plans for fiscal 2019 was $1.34M, a 1661.84% increase from fiscal 2018.
- Turning Point Therapeutics, Inc. proceeds from stock plans for fiscal 2018 was $76.00K.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2022-06-30 | $8.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $9.37M 10-Q · filed 2022-08-08 | $11.97M derived: sum of 3 quarters · filed 2022-08-08 | $14.35M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $396.00K 10-Q · filed 2022-05-10 | $3.00M derived: sum of 2 quarters · filed 2022-05-10 | $5.38M derived: sum of 3 quarters · filed 2022-05-10 | $14.72M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.98M derived: sum of 2 quarters · filed 2022-02-28 | $14.32M derived: sum of 3 quarters · filed 2022-08-08 | $24.00M 10-K · filed 2022-02-28 |
| 2021-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $11.72M derived: sum of 2 quarters · filed 2022-08-08 | $21.40M 10-Q · filed 2021-11-09 | $33.60M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | $9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $19.02M 10-Q · filed 2022-08-08 | $31.22M derived: sum of 3 quarters · filed 2022-08-08 | $31.73M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $9.68M 10-Q · filed 2022-05-10 | $21.88M derived: sum of 2 quarters · filed 2022-05-10 | $22.39M derived: sum of 3 quarters · filed 2022-05-10 | $22.92M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $12.71M derived: sum of 2 quarters · filed 2022-02-28 | $13.24M derived: sum of 3 quarters · filed 2022-02-28 | $13.27M 10-K · filed 2022-02-28 |
| 2020-09-30 | $508.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.04M derived: sum of 2 quarters · filed 2021-11-09 | $1.07M 10-Q · filed 2021-11-09 | $1.70M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $535.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $560.00K 10-Q · filed 2021-08-09 | $1.19M derived: sum of 3 quarters · filed 2022-02-28 | $1.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $25.00K 10-Q · filed 2021-05-05 | $655.00K derived: sum of 2 quarters · filed 2022-02-28 | $751.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $630.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $726.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.34M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $709.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $613.00K 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $76.00K 10-K · filed 2021-03-01 |